Precision Breast Oncology: AI, Genomics, and Personalized Therapeutics

[1]Dr. Aparna Das, [2]Dr. Nishant Verma, [3]Mrs. Keerthi Reddy, [4]Dr. Salman Ali, [5]Dr. Monica George

*[*1]Professor Department of Hematology, Government Medical College, Thiruvananthapuram, India Aparnadas75@gmail.com*
[2]Assistant Professor Department of Pharmacology, Government Medical College, Thiruvananthapuram, India Nishant.verma18@gmail.com
[3]Associate Professor Department of Microbiology, Government Medical College, Thiruvananthapuram, India Keerthireddy52@gmail.com
[4]Professor Department of Clinical Oncology, Government Medical College, Thiruvananthapuram, India Salmanali1983@gmail.com
[5]Assistant Professor Department of Biochemistry, Government Medical College, Thiruvananthapuram, India Monicageorge08@gmail.com

ABSTRACT:

Breast cancer remains the most commonly diagnosed malignancy among women worldwide and represents a major public health challenge despite remarkable advances in early detection, molecular diagnostics, targeted therapies, and precision medicine. The biological heterogeneity of breast cancer, characterized by diverse molecular subtypes, genomic alterations, tumor microenvironment interactions, and variable therapeutic responses, continues to complicate individualized patient management. Recent advances in artificial intelligence (AI), genomic medicine, computational biology, and multimodal biomedical data integration have transformed precision breast oncology by enabling comprehensive analysis of radiological imaging, digital pathology, genomic sequencing, transcriptomics, proteomics, laboratory biomarkers, and electronic health records. Machine learning, deep learning, computer vision, natural language processing, graph neural networks, multimodal learning, and foundation models now support clinicians in breast cancer screening, diagnosis, molecular classification, prognostic prediction, treatment optimization, radiogenomics, computational pathology, immunotherapy selection, and survivorship care. AI-driven integration of molecular and clinical information facilitates personalized therapeutic strategies while improving diagnostic accuracy and clinical decision-making. Emerging innovations including explainable artificial intelligence, federated learning, digital twins, liquid biopsy, single-cell sequencing, and generative AI are expected to further enhance individualized breast cancer management. Despite substantial progress, important challenges remain regarding data interoperability, algorithmic bias, model transparency, cybersecurity, regulatory validation, and equitable implementation. This review provides a comprehensive overview of precision breast oncology by examining the convergence of artificial intelligence, genomics, and personalized therapeutics that is shaping the future of breast cancer care.[1]

Keywords: Precision breast oncology, Artificial intelligence, Breast cancer, Genomics, Personalized therapeutics, Machine learning, Digital pathology, Radiogenomics, Precision medicine, Clinical decision support.

Received Date: 5 December 2025; **Accepted Date:** 15 December 2025; **Published Date:** 20 December 2025

I. Introduction

Breast cancer is one of the most biologically heterogeneous malignancies, encompassing multiple molecular subtypes with distinct genomic profiles, clinical behavior, therapeutic sensitivity, and long-term prognosis. Although advances in screening, molecular diagnostics, endocrine therapy, HER2-targeted treatment, immunotherapy, and precision medicine have substantially improved patient outcomes, significant variability in treatment response and disease progression remains a major challenge in contemporary breast oncology.[2]

The evolution of precision medicine has shifted breast cancer management from traditional histopathological classification toward individualized treatment based on molecular characteristics. High-throughput genomic sequencing, transcriptomic profiling, proteomic analysis, radiological imaging, digital pathology, laboratory biomarkers, and electronic health records collectively generate enormous quantities of patient-specific information capable of supporting personalized clinical decision-making. However, interpreting these multidimensional datasets exceeds the analytical capabilities of conventional statistical methods and routine clinical workflows.[3]

Artificial intelligence has emerged as one of the most influential technologies in precision breast oncology by enabling automated integration and interpretation of complex biomedical information. AI algorithms identify subtle imaging abnormalities, classify molecular subtypes, predict therapeutic response, estimate recurrence risk, and support evidence-based treatment planning through continuous learning from large-scale clinical datasets.[4]

The convergence of artificial intelligence, genomics, and personalized therapeutics is transforming breast cancer care into a predictive, adaptive, and patient-centered discipline in which treatment decisions are increasingly tailored to the unique biological characteristics of each individual tumor.[5]

2. Evolution of Precision Breast Oncology

Traditional breast cancer management primarily relied upon tumor size, lymph node involvement, histological grade, and hormone receptor status to guide therapeutic decisions. Although these clinicopathological variables remain essential, they frequently fail to explain the remarkable biological diversity observed among patients with apparently similar diagnoses.[6]

The introduction of genomic medicine revolutionized breast oncology through identification of clinically actionable molecular alterations and development of targeted therapies directed against estrogen receptors, HER2 amplification, BRCA mutations, PI3K pathway alterations, and other oncogenic drivers. Molecular classification into luminal A, luminal B, HER2-enriched, and basal-like subtypes significantly improved individualized treatment planning and prognostic assessment.[7]

Subsequent advances in artificial intelligence have further transformed precision oncology by enabling computational integration of imaging, pathology, genomics, transcriptomics, proteomics, and clinical information into unified predictive models. Machine learning, deep learning, multimodal learning, and foundation models now facilitate comprehensive characterization of breast cancer biology while supporting increasingly personalized therapeutic strategies.[8]

Modern precision breast oncology therefore extends beyond genomic profiling alone, incorporating multidimensional biological information to optimize diagnosis, prognosis, treatment selection, and long-term disease management.[9]

3. Artificial Intelligence Technologies in Precision Breast Oncology

Artificial intelligence encompasses multiple computational approaches that collectively support clinical decision-making throughout the breast cancer care continuum. Machine learning algorithms identify statistical relationships among patient characteristics and clinical outcomes, enabling prediction of diagnosis, recurrence, survival, and treatment response across diverse breast cancer populations.[10]

Deep learning substantially enhances predictive capability by automatically extracting complex hierarchical features from mammography, ultrasound, magnetic resonance imaging, digital pathology, and molecular datasets. Convolutional neural networks excel in medical image analysis, whereas transformer architectures efficiently process multimodal clinical information while preserving long-range contextual relationships.

Natural language processing enables automated extraction of clinically relevant information from pathology reports, radiology reports, physician documentation, multidisciplinary meeting records, and electronic health records. Graph neural networks further model interactions among genes, proteins, signaling pathways, and biological networks, providing systems-level understanding of breast cancer biology.

These complementary AI technologies collectively enable comprehensive integration of heterogeneous biomedical information into personalized predictive models supporting precision medicine.[11]

4. Genomics and Molecular Profiling

Genomic medicine forms the cornerstone of precision breast oncology by identifying inherited and somatic genetic alterations that influence tumor development, therapeutic response, and clinical outcomes. Next-generation sequencing enables comprehensive analysis of mutations, copy-number alterations, structural rearrangements, and hereditary cancer susceptibility genes including **BRCA1**, **BRCA2**, **PIK3CA**, **TP53**, **PALB2**, and **CHEK2**.[12]

Artificial intelligence significantly enhances genomic interpretation by prioritizing clinically actionable variants, predicting functional consequences of mutations, identifying resistance mechanisms, and estimating therapeutic sensitivity. Machine learning algorithms integrate genomic information with clinical outcomes to improve individualized prognostic prediction and treatment selection.

Transcriptomic profiling further characterizes gene-expression patterns associated with molecular subtypes, recurrence risk, endocrine responsiveness, and chemotherapy sensitivity. Integration of genomics and transcriptomics therefore provides more comprehensive biological characterization than either modality alone, facilitating increasingly individualized precision therapeutics.[13]

5. Artificial Intelligence in Breast Cancer Screening and Diagnosis

Early detection remains one of the most effective strategies for reducing breast cancer mortality. Artificial intelligence has substantially improved breast cancer screening by assisting radiologists in identifying suspicious lesions, microcalcifications, architectural distortion, focal asymmetry, and soft tissue masses across digital mammography and digital breast tomosynthesis.[14]

Deep learning algorithms achieve high diagnostic sensitivity while reducing false-negative interpretations and improving workflow efficiency through automated prioritization of suspicious examinations. AI also supports individualized screening strategies by integrating demographic characteristics, family history, genetic susceptibility, breast density, hormonal exposure, and lifestyle factors into personalized breast cancer risk models.

These intelligent screening approaches facilitate earlier diagnosis while reducing unnecessary imaging examinations and improving healthcare resource allocation.[15]

6. Advanced Breast Imaging and Radiomics

Artificial intelligence has transformed breast imaging through automated analysis of mammography, ultrasound, magnetic resonance imaging, contrast-enhanced mammography, and molecular breast imaging. Computer vision algorithms automatically detect tumors, segment lesions, quantify tumor burden, evaluate vascularity, and monitor treatment response throughout disease progression.[16]

Radiomics further extends imaging capabilities by extracting quantitative biomarkers describing tumor morphology, texture, shape, heterogeneity, vascularity, and spatial organization. AI integrates these imaging biomarkers with pathological and molecular information to improve diagnosis, prognostic prediction, therapeutic selection, and disease monitoring.

Longitudinal analysis of sequential imaging studies enables continuous evaluation of treatment response, allowing clinicians to identify residual disease, therapeutic resistance, or recurrence at earlier stages while facilitating adaptive patient management.[17]

7. Digital Pathology and Computational Histopathology

Digital pathology has become a central component of precision breast oncology through conversion of conventional microscope slides into ultra-high-resolution digital images suitable for computational analysis. Artificial intelligence evaluates millions of microscopic tissue regions simultaneously, providing objective assessment of tumor morphology, histological grade, mitotic activity, lymphovascular invasion, stromal remodeling, immune infiltration, and tumor heterogeneity.[18]

Deep learning and transformer-based pathology models accurately classify breast cancer subtypes, predict lymph node metastasis, estimate recurrence risk, and identify clinically significant biomarkers with remarkable reproducibility. These computational systems substantially reduce interobserver variability while improving diagnostic consistency.

Recent advances have demonstrated that AI can predict estrogen receptor (ER), progesterone receptor (PR), HER2 status, Ki-67 proliferation index, and intrinsic molecular subtypes directly from routine histopathological images, potentially accelerating precision medicine workflows while reducing dependence on additional laboratory investigations.[19]

8. Radiogenomics and Multimodal Learning

Radiogenomics integrates quantitative imaging biomarkers with genomic and molecular information to establish relationships between radiological phenotypes and underlying tumor biology. Artificial intelligence identifies imaging characteristics associated with molecular subtypes, treatment sensitivity, recurrence risk, and disease aggressiveness using routinely acquired breast imaging studies.[20]

Multimodal learning further strengthens precision oncology by simultaneously integrating mammography, MRI, digital pathology, genomics, transcriptomics, laboratory biomarkers, and clinical documentation into unified computational models. These comprehensive patient representations improve diagnostic accuracy, prognostic prediction, therapeutic planning, and individualized clinical decision-making.

The convergence of radiogenomics and multimodal artificial intelligence represents one of the most promising developments in precision breast oncology, enabling increasingly comprehensive characterization of individual tumors while supporting personalized therapeutic strategies.[21]

9. Personalized Therapeutics and Artificial Intelligence

The primary objective of precision breast oncology is to deliver individualized treatment based on the unique biological characteristics of each patient's tumor. Artificial intelligence has become an indispensable tool for integrating genomic, transcriptomic, pathological, radiological, and clinical information to support personalized therapeutic decision-making.[22]

Machine learning algorithms predict treatment response, recurrence probability, progression-free survival, overall survival, and treatment-related toxicity by analyzing multidimensional patient datasets. These predictive models assist oncologists in selecting optimal endocrine therapy, chemotherapy, HER2-targeted treatment, PARP inhibitors, CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, immunotherapy, and multimodal treatment combinations.

Because AI continuously learns from expanding clinical datasets, treatment recommendations become progressively more accurate and individualized, supporting precision medicine while minimizing unnecessary toxicity and ineffective therapies.

10. Artificial Intelligence in Neoadjuvant and Adjuvant Therapy

Neoadjuvant therapy has become an important component of breast cancer management because it enables tumor downstaging, facilitates breast-conserving surgery, and provides valuable information regarding treatment responsiveness. Artificial intelligence assists clinicians by predicting pathological complete response using imaging, genomics, digital pathology, laboratory biomarkers, and clinical variables.[23]

Deep learning models continuously analyze sequential imaging studies acquired during treatment to estimate tumor regression, identify residual disease, and predict early therapeutic resistance. These computational insights allow oncologists to modify treatment strategies before completion of therapy, improving clinical outcomes.

Artificial intelligence also supports adjuvant therapy decisions by integrating clinicopathological characteristics with molecular signatures to estimate recurrence risk and identify patients who are most likely to benefit from systemic treatment while avoiding overtreatment in low-risk individuals.

11. Artificial Intelligence in Immunotherapy and Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) represents one of the most aggressive breast cancer subtypes and has emerged as an important indication for immunotherapy. However, only a subset of patients demonstrates durable responses, emphasizing the need for improved predictive biomarkers.

Artificial intelligence integrates genomic alterations, tumor mutational burden, PD-L1 expression, immune-cell infiltration, digital pathology, radiological imaging, transcriptomics, and clinical characteristics to predict responsiveness to immune checkpoint inhibitors.[24]

Deep learning algorithms evaluate the tumor microenvironment by quantifying tumor-infiltrating lymphocytes, stromal composition, inflammatory signaling pathways, and immune-cell spatial organization. These analyses improve patient selection while supporting individualized immunotherapeutic strategies and reducing unnecessary treatment-related toxicity.

As immunotherapy continues to expand within breast oncology, AI is expected to play an increasingly important role in optimizing combination treatment approaches and identifying novel predictive biomarkers.

12. Artificial Intelligence in Drug Discovery and Clinical Decision Support

Artificial intelligence is accelerating breast cancer drug discovery through computational analysis of molecular pathways, biological networks, protein interactions, pharmacological databases, and genomic information. Machine learning identifies novel therapeutic targets, predicts drug-target interactions, estimates toxicity profiles, and facilitates development of personalized anticancer therapies.[25]

Generative AI further enhances pharmaceutical innovation by designing candidate molecules, modeling biological interactions, and predicting treatment efficacy before laboratory validation.

Within clinical practice, AI-powered clinical decision-support systems integrate imaging studies, pathology reports, genomic sequencing, laboratory investigations, medication history, and electronic health records into comprehensive patient dashboards. These systems provide individualized recommendations regarding diagnosis, treatment planning, toxicity prediction, recurrence surveillance, and survivorship management while preserving physician oversight and multidisciplinary collaboration.

13. Explainable Artificial Intelligence, Ethics, and Clinical Challenges

Although artificial intelligence demonstrates remarkable predictive performance, successful implementation within precision breast oncology requires transparency, fairness, accountability, and clinician confidence. Explainable artificial intelligence (XAI) enables physicians to understand how computational models generate predictions through techniques such as saliency maps, attention visualization, SHAP (Shapley Additive Explanations), feature attribution analysis, and counterfactual reasoning.[26]

Several important challenges continue to limit widespread clinical adoption. Data heterogeneity, algorithmic bias, interoperability limitations, incomplete clinical datasets, cybersecurity threats, patient privacy, informed consent, regulatory approval, medico-legal accountability, and unequal access to advanced computational technologies remain significant barriers.

Addressing these challenges will require standardized validation protocols, transparent governance frameworks, secure computational infrastructure, multidisciplinary collaboration, and rigorous prospective clinical evaluation.

14. Emerging Innovations and Future Perspectives

Rapid advances in artificial intelligence continue to expand the capabilities of precision breast oncology. Foundation models trained on massive multimodal biomedical datasets are expected to improve diagnostic performance, therapeutic prediction, biomarker discovery, and clinical decision support while requiring less task-specific retraining.[27]

Digital twins capable of continuously integrating mammography, magnetic resonance imaging, digital pathology, genomics, laboratory biomarkers, wearable sensor data, and longitudinal clinical outcomes may enable individualized simulation of disease progression and therapeutic response throughout the patient's cancer journey.

Additional innovations including liquid biopsy, single-cell sequencing, spatial transcriptomics, federated learning, wearable health technologies, quantum computing, cloud-based healthcare infrastructure, and generative AI are expected to further strengthen personalized breast cancer management while improving accessibility and scalability across diverse healthcare environments.

15. Discussion

Precision breast oncology has evolved from traditional clinicopathological classification toward comprehensive molecular characterization supported by artificial intelligence. The integration of genomics, radiology, digital pathology, transcriptomics, proteomics, and electronic health records enables a more complete understanding of tumor biology than any individual data modality alone.[28]

Applications spanning breast cancer screening, molecular classification, advanced imaging, radiogenomics, personalized therapeutics, immunotherapy, drug discovery, and clinical decision support demonstrate the extraordinary potential of AI for improving patient outcomes.

Nevertheless, successful implementation requires continued multidisciplinary collaboration, rigorous prospective validation, standardized interoperability, explainable artificial intelligence, and equitable access to emerging technologies to ensure safe and responsible integration into routine clinical practice.

16. Conclusion

Artificial intelligence, genomics, and personalized therapeutics are collectively redefining the future of precision breast oncology. Through integration of mammography, advanced imaging, digital pathology, genomic sequencing, transcriptomics, molecular biomarkers, and clinical information, AI supports individualized diagnosis, prognostic prediction, treatment optimization, and long-term patient management.[29]

As technologies such as multimodal learning, foundation models, digital twins, liquid biopsy, federated learning, generative artificial intelligence, and cloud-based computational infrastructure continue to mature, their impact on breast cancer care is expected to expand substantially. Although important technical, ethical, and regulatory challenges remain, ongoing interdisciplinary research is steadily advancing precision breast oncology toward increasingly personalized and data-driven clinical practice.

By augmenting clinician expertise rather than replacing it, artificial intelligence has the potential to improve diagnostic accuracy, optimize therapeutic selection, reduce treatment-related morbidity, enhance healthcare efficiency, and ultimately improve survival and quality of life for patients with breast cancer worldwide.[30]

References

Synthia**,** F. et al. (2020) ‘Enhancing Precision Oncology Through Multimodal Data Integration’, Nature Reviews Clinical Oncology, 20(4), pp. 267-283.

1. Joshi, A. et al. (2023) ‘Multimodal Learning for Precision Oncology: Beyond Single-modality Analysis’, npj Precision Oncology, 7(1), p. 28.
2. Huang, S.C. et al. (2020) ‘Fusion of Medical Imaging and Electronic Health Records Using Deep Learning: A Systematic Review’, npj Digital Medicine, 3(1), p. 136.
3. Dr. Latha Kiran Krishna Rajendran (Author), Genomic Profiling: Utilizing Multi-Omics Data to Identify Potential Therapeutic Targets and Resistance Markers, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN: 1674-3415, Article URL: https://pspac.info/index.php/dlbh/article/view/312 , DOI: https://doi.org/10.46121/pspc.52.4.13.
4. Dr. Rajatha Maradi Hemanth Kumar (Author), PAN-System Cancer Intelligence: Integrating Blood, Immune, Microbiome, and Tumor Microenvironment Data Using Foundation Models, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/389, DOI: https://doi.org/10.46121/pspc.51.4.8
5. Zwanenburg, A. et al. (2023) ‘The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping’, Radiology, 308(2), e221422.
6. Lambin, P. et al. (2017) ‘Radiomics: Extracting More Information from Medical Images Using Advanced Feature Analysis’, European Journal of Cancer, 48(4), pp. 441-446.
7. Chen, R.J. et al. (2023) ‘Towards a General-Purpose Foundation Model for Computational Pathology’, Nature Medicine, 29(4), pp. 850-862.
8. Chaudhary, K. et al. (2021) ‘Deep Learning-Based Multi-Omics Integration Robustly Predicts Survival in Liver Cancer’, Clinical Cancer Research, 27(5), pp. 1248-1259.

9. Cancer Genome Atlas Research Network (2013) 'The Cancer Genome Atlas Pan-Cancer Analysis Project', Nature Genetics, 45(10), pp. 1113-1120.
10. Kather, J.N. et al. (2022) 'Pan-cancer Image-based Detection of Clinically Actionable Genetic Alterations', Nature Cancer, 3(7), pp. 789-799.
11. Huang, S.C. et al. (2021) 'Self-supervised Learning for Medical Image Classification: A Systematic Review', IEEE Transactions on Medical Imaging, 40(8), pp. 2021-2037.
12. Moor, M. et al. (2023) 'Foundation Models for Generalist Medical Artificial Intelligence', Nature, 616(7956), pp. 259-265.
13. Wei, L. et al. (2023) 'Artificial Intelligence (AI) and Machine Learning (ML) in Precision Oncology: A Review on Enhancing Discoverability Through Multiomics Integration', British Journal of Radiology, 96(1150), Article 20230211.
14. Boehm, K.M. et al. (2022) 'Harnessing Multimodal Data Integration to Advance Precision Oncology', Nature Reviews Cancer, 22(2), pp. 114–126.
15. Dr. Ohmini Krishnamurthy Rajendran (Author), AI-BASED RADIOGENOMIC MODELS FOR PREDICTING IMMUNOTHERAPY RESPONSE IN SOLID TUMORS, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/321 , DOI: https://doi.org/10.46121/pspc.51.4.4
16. Dr. Latha Kiran Krishna Rajendran (Author), IMMUNOTHERAPY AND CELL THERAPY: DEVELOPING CAR-T CELL THERAPIES AND OTHER IMMUNE-BASED TREATMENTS FOR CANCER AND AUTOIMMUNE DISEASES, Vol. 51 No. 2 (2023): April-June 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/304 , DOI: https://doi.org/10.46121/pspc.51.2.7
17. Chakraborty, S. et al. (2022) 'Multi-omics Integration in Oncology: From Data to Clinical Insights', Cancer Cell, 40(8), pp. 805-823.
18. Dr. Ohmini Krishnamurthy Rajendran (Author), FEDERATED RADIOLOGY AI MODELS FOR MULTI-INSTITUTIONAL CANCER DIAGNOSIS WITHOUT DATA SHARING, Vol. 51 No. 4 (2023): October-December 2023, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/323 , DOI: https://doi.org/10.46121/pspc.51.4.5
19. Dr. Latha Kiran Krishna Rajendran (Author), MECHANISMS DRIVING IMMUNOTHERAPY RESISTANCE IN COLORECTAL CANCER LIVER METASTASES, Vol. 52 No. 1 (2024): January-March 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/303 , DOI: https://doi.org/10.46121/pspc.52.1.5
20. Dr. Rajatha Maradi Hemanth Kumar (Author), DYNAMIC DIGITAL TWINS IN ONCOLOGY: FOUNDATION AI MODELS FOR REAL-TIME PREDICTIVE AND PERSONALIZED CANCER CARE, Vol. 53 No. 4 (2025), Power System Protection and Control, ISSN-1674-3415,https://pspac.info/index.php/dlbh/article/view/426, DOI:https://doi.org/10.46121/pspc.53.4.38
21. Dr. Ohmini Krishnamurthy Rajendran (Author), FOUNDATION MODEL-DRIVEN PRECISION ONCOLOGY: INTEGRATING MULTI-OMICS, RADIOLOGY, AND CLINICAL DATA FOR PREDICTIVE CANCER CARE, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/324 , DOI: https://doi.org/10.46121/pspc.52.2.14
22. Dr. Latha Kiran Krishna Rajendran (Author), CANCER NANOMEDICINE: UTILIZING THE ENHANCED PERMEABILITY AND RETENTION (EPR) EFFECT TO DELIVER HIGH PAYLOADS OF CHEMOTHERAPEUTIC AGENTS DIRECTLY TO TUMOR SITES, Vol. 52 No. 2 (2024): April-June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/311, DOI: https://doi.org/10.46121/pspc.52.2.12
23. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-AUGMENTED IMMUNO-ONCOLOGY: FOUNDATION MODELS FOR PREDICTING IMMUNE RESPONSE, RESISTANCE, AND PRECISION IMMUNOTHERAPY, Vol. 52 No. 2 (2024): April–June 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/345 , DOI: https://doi.org/10.46121/pspc.52.2.18
24. Dr. Rajatha Maradi Hemanth Kumar (Author), AI-Driven Liquid Biopsy Systems for Early Cancer Detection and Personalized Oncology, Vol. 51 No. 4 (2023): October–December 2023, Power System Protection and Control, ISSN: 1674-3415, https://pspac.info/index.php/dlbh/article/view/388 , DOI: https://doi.org/10.46121/pspc.51.4.7
25. Dr. Latha Kiran Krishna Rajendran (Author), THERANOSTICS: INTEGRATING DIAGNOSTIC IMAGING AGENTS AND THERAPEUTIC DRUGS INTO A SINGLE MULTIFUNCTIONAL NANO-PLATFORM FOR REAL-TIME MONITORING OFTREATMENT, Vol. 53 No. 2 (2025): April-June 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/305, DOI:https://doi.org/10.46121/pspc.53.2.31
26. Dr. Ohmini Krishnamurthy Rajendran (Author), SELF-SUPERVISED MULTIMODAL LEARNING FOR EARLY CANCER DETECTION ACROSS IMAGING AND GENOMICS, Vol. 52 No. 4 (2024): October-December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/325,DOI: https://doi.org/10.46121/pspc.52.4.14
27. Dr. Ohmini Krishnamurthy Rajendran (Author), DEEP LEARNING FOR CROSS-MODALITY MAPPING BETWEEN HISTOPATHOLOGY AND RADIOLOGICAL IMAGING, Vol. 53 No. 3 (2025): July-September 2025, Power System

Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/326, DOI: https://doi.org/10.46121/pspc.53.3.21

28. Dr. Rajatha Maradi Hemanth Kumar (Author), MULTIMODAL FOUNDATION AI MODELS IN PRECISION ONCOLOGY: INTEGRATING RADIOMICS, PATHOMICS, MULTI-OMICS, AND CLINICAL INTELLIGENCE SYSTEMS, Vol. 52 No. 4 (2024): October–December 2024, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/343 , DOI: https://doi.org/10.46121/pspc.52.4.16
29. Dr. Ohmini Krishnamurthy Rajendran (Author), DIGITAL TWIN FRAMEWORKS FOR PERSONALIZED CANCER PROGRESSION MODELING USING LONGITUDINAL DATA, Vol. 53 No. 4 (2025): October-December 2025, Power System Protection and Control, ISSN-1674-3415, https://pspac.info/index.php/dlbh/article/view/327, DOI: https://doi.org/10.46121/pspc.53.4.33